MET and glioblastoma: Particularly, Met, the tyrosine kinase receptor of hepatocyte growth factor receptor (HGF), is a well-known potential target since it is overexpressed in different types of cancer, as colon rectal carcinoma [26], glioblastoma [27] and breast carcinoma [28] and it has been successfully used as a targeting agent when coupled to MNPs [6,8,29].